## SDGR: Schrodinger, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: PEG 1.30 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($16.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. BofA Securities upgrades Schrodinger stock rating to Buy from Neutral By Investing.com**
- Source: Investing.com Canada | 20251215T150926 | Bullish | Relevance: 100%
- BofA Securities has upgraded Schrodinger (NASDAQ:SDGR) from Neutral to Buy, citing the company's refocused business strategy on software operations. This shift has led to improved revenue growth and a "cleaner story" for the company, with analysts expecting benefits from the pharmaceutical R&D cycle. The upgrade follows Schrodinger's positive Q3 2025 earnings report, which surpassed EPS and revenue forecasts.

**2. B of A Securities Upgrades Schrödinger (SDGR)**
- Source: Nasdaq | 20251215T140926 | Bullish | Relevance: 100%
- B of A Securities has upgraded Schrödinger (NASDAQ:SDGR) from Neutral to Buy, with an average one-year price target of $27.77, suggesting a 53.83% upside from its current price. Institutional ownership data shows mixed activity, with some firms like Bill & Melinda Gates Foundation Trust maintaining stakes, while others like Rubric Capital Management and IJR have adjusted their holdings. The company's projected annual revenue is 505MM, a 96.71% increase, and a non-GAAP EPS of 0.05.

**3. Schrodinger (SDGR) Upgraded to Buy by B of A Securities | SDGR S**
- Source: GuruFocus | 20251215T130926 | Bullish | Relevance: 100%
- B of A Securities has upgraded Schrodinger (SDGR) from Neutral to Buy, maintaining a price target of $24.00. This upgrade comes amidst varying analyst ratings, with other firms like Keybanc and Goldman Sachs holding Overweight and Neutral ratings, respectively. Wall Street analysts project an average target price of $27.22 for SDGR, implying a potential upside of 50.82% from its current price, and GuruFocus estimates a fair value of $35.04.

**4. Schrodinger, Inc. $SDGR Shares Purchased by Nikko Asset Management Americas Inc.**
- Source: MarketBeat | 20251214T110844 | Neutral | Relevance: 100%
- Nikko Asset Management Americas Inc. increased its stake in Schrodinger, Inc. (NASDAQ:SDGR) by 7.2% in the second quarter, owning over 2.59 million shares worth $52.09 million. Other institutional investors like Rubric Capital Management LP and UBS AM also significantly boosted their holdings. The article also notes recent analyst rating changes and an insider stock sale by Margaret Dugan.

**5. Wall Street Analysts Believe Schrodinger (SDGR) Could Rally 46.17%: Here's is How to Trade**
- Source: Your Wyoming Link | 20251213T120914 | Bullish | Relevance: 100%
- Wall Street analysts project a potential upside of 46.2% for Schrodinger (SDGR), with a mean price target of $26.5. Despite skepticism around price targets, analysts' increasing optimism regarding the company's earnings prospects and a Zacks Rank #2 (Buy) suggest a potential rally in the stock. Investors are advised to consider earnings estimate revisions and the Zacks Rank as more reliable indicators than just price targets.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $24 | $24 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.03M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.8% (-2.2%)
- Gates Foundation Tru: 10.8% (0.0%)
- Vanguard Group Inc: 9.8% (-4.2%)
- Rubric Capital Manag: 8.2% (+5.4%)
- Sumitomo Mitsui Trus: 7.1% (+24.8%)

### Key Risks

1. High short interest (25.5%, 10.0 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 12.7% below SMA200.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Momentum building: MRS_10 improving +3.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.30 suggests fair value with growth premium. Balance sheet: strong liquidity (3.2x). Revenue growth strong at 20% YoY. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 1.57 |
| 52W Range | $15.99 - $28.47 |
| Short Interest | 25.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.30 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from 0.3% to 3.6% (+3.4% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 69th percentile. MRS_5 at 2.6% confirms short-term momentum alignment. Below SMA200 (0.87x), long-term trend not supportive. RSI neutral at 52. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.64% (CS: 70) | Strong |
| RSI_14 | 51.5 | Neutral |
| MACD Histogram | 0.20 | Bullish |
| vs SMA20 | 1.042x | Above |
| vs SMA50 | 0.957x | Below |
| vs SMA200 | 0.873x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.21
- **Stop Loss:** $16.55 (9.1% risk)
- **Target:** $19.87 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 722
- **Position Value:** $13,147.62
- **Portfolio %:** 13.15%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.74 | $-0.57 | +23.0% |
| 2025Q2 | $-0.64 | $-0.65 | -1.6% |
| 2025Q1 | $-0.81 | $-0.64 | +21.0% |
| 2024Q4 | $-0.38 | $-0.24 | +36.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*